BINDING ANTIBODY TO NEUTRALIZING EPITOPE GP41 IN HIV-1 SUBTYPE CRF 01_AE INFECTION RELATED TO STAGE OF DISEASE
|
|
- Holly McLaughlin
- 5 years ago
- Views:
Transcription
1 BINDING ANTIBODY TO NEUTRALIZING EPITOPE GP41 IN HIV-1 SUBTYPE CRF 01_AE INFECTION RELATED TO STAGE OF DISEASE Surangrat Srisurapanon 1, Suda Louisirirotchanakul 2, Kwonchit Sumransurp 1, Monthaswad Ratanasrithong 3 Thippawan Chuenchitra 4, Siriporn Jintakatkorn 3 and Chantapong Wasi 2 1 Department of Pathology, Faculty of Medicine, Srinakharinwirot University, Bangkok; 2 Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok; 3 Bamrasnaradura Institute, Communicable Disease Control Department, Ministry of Health, Nonthaburi; 4 Armed Forces Research Institute of Medical Science, Bangkok, Thailand Abstract. The responsiveness of gp41 antibody against epitope ELDKWA in HIV-1 infected subjects is of importance in neutralizing viral infectivity and for being related to disease progression. In this study, antibody titers to this neutralizing epitope from HIV-1 infected subjects at asymptomatic and AIDS stages in Thailand were investigated by peptide ELISA. The results showed that the frequency of antibody production against this neutralizing epitope was low (15-35%). Moreover, antibody titers to this epitope in sera from AIDS patients were significantly lower than those in sera from asymptomatic subjects which were collected in the same year (p=0.001). Comparison between the past ( ) and present (2002) sera from asymptomatic infected individuals revealed that the earlier panel contained lower antibody titers than the later panel did (p=0.05). In addition, random sera for HIV-1 infected subjects who were infected by diverse genetic subtypes, (A through G) including CRF 01_AE, had low titers of antibody to this region as well. It is assumed that antibody production to this epitope is low and related to the stage of HIV-1 infection. INTRODUCTION Correspondence: Dr Surangrat Srisurapanon, Department of Pathology, Faculty of Medicine, Srinakharinwirot University, Sukumvit 23, Sukumvit Road, Wattana, Bangkok 10110, Thailand. Tel: +66 (0) ext Human immunodeficiency virus-type 1 (HIV- 1) infection elicits antibodies directed against several regions of gp120 and gp41 envelope glycoproteins. A highly conserved gp41 epitope (amino acid sequence ELDKWA) has been described to elicit antibodies neutralizing a broad variety of HIV-1 strains (Calarota et al, 1996). The natural occurrence of HIV-1-specific neutralizing antibodies in HIV-1 infected individuals was first described in 1985 (Robert-Guroff et al, 1985; Weiss et al, 1985). Most patients with primary HIV infection rapidly generated significant neutralizing antibody responses to early (0-39 months) autologous viruses (Richman et al, 2003). Consequently, neutralizing escape mutants were found rapidly in the majority of HIV-1 infected patients. The quality of the antibody response changed significantly and was not able to neutralize plasma virus (Albert et al, 1990). Only a few HIV- infected patients produced antibodies that neutralized a broad range of HIV-1 strains (Stiegler and Katinger, 2003). In this group, a correlation between the presence of neutralizing antibodies and the protective effect in HIV infection has been reported (Ariyoshi et al, 1992). In serological studies, evidence confirms that one of the broad and potent neutralizing antibodies reacted with an immunogenic epitope on gp41 defined by 2F5 human monoclonal antibody (Mab). This Mab also reacts with the short peptide ELDKWA, corresponding to the linear conserved region (ELDKWAS) of gp41 cluster II (Neurath et al, 1995; Purtscher et al, 1996). A previous study of Mab to this epitope reported that 2F5 and 2G12 passively administrated to macaques were able to confer protection from both intravenous and mucosal challenge with pathogenic HIV-simian immunodeficiency virus chimeric strains and has shown beneficial effects in phase 1 clinical trials (Wolbank et al, 2003). Other studies reported Vol 36 No. 1 January
2 SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH that the native structure of this epitope was unexposed and affected significantly by other regions (Nyambi et al, 1998; Biron et al, 2002). However, It has been observed that production of neutralizing antibody to this epitope (ELDKWA) has been related to slow disease progression (Stiegler et al, 2002). This may suggest that the antibody to this epitope is related to disease progression. In predicting disease progression, a number of biological markers, such as viral load, CD4+T lymphocyte counts, CD38 molecules and other activated molecules, have been followed. These confounding factors may be related to the level of neutralizing antibody against this epitope. However, the relationship between the levels of this antibody and the stage of disease is unclear. The dynamic response of antibody to this conserved region, and how this epitope is related to genetic subtypes, is poorly understood. Therefore, we investigated the frequency and titers of antibody to this region of gp41 in the sera of HIV-1 infected subjects at different stages of disease. MATERIALS AND METHODS Study patients and serum bank In 2002, after obtaining consent forms, 242 blood samples from HIV-1 infected subjects, consisting of 171 subjects in the AIDS stage and 71 subjects in asymptomatic stage, based on 1994 CDC staging system, were obtained. These samples were collected from HIV-1 infected individuals at Bamrasnaradura Institute in Bangkok, Thailand. The mode of transmission in these subjects was sexual transmission. All, except 9, asymptomatic persons were treated with antiretroviral therapy (using one protease inhibitor and two nucleoside reverse transcriptase inhibitors). Subtypes of these samples were determined by peptide ELISA. In addition, two other panels with known subtypes of HIV-1 sera, which were part of a serum repository collected in , were included. The first panel (n=58) belonged to asymptomatic HIV-1 subtype CRF 01_AE infected patients in Thailand. The second panel (n=184) collected from HIV-1 diverse genetic subtypes (A to G) was random. All sera were stored at -20ºC until tested. Although this was a cross-sectional study, longitudinal information regarding plasma RNA levels, CD3+, CD4+, CD8+T-cell counts, antiretroviral therapy, opportunistic infections and modes of transmission, were abstracted from the medical records. Complete blood counts, CD3+, CD4+, CD8+ T-cell counts, HIV- RNA and levels of antibody to gp41 were performed simultaneously (Table 1). Lymphocyte Table 1 Clinical and immunological characteristics of HIV-1 subtype CRF 01_AE infected patients. Asymptomatic patients Disease stage AIDS HIV-1 CRF 01_AE (n=171) (n=58) (n=71) Antiretroviral treatment Yes No CD4 ( x10 6 cells/l) Min-max ND Mean ± SD 356.4± ±65.9 CD8 ( x10 6 cellsl) Min-max ND Mean ± SD ± ±445.2 Viral load (copies/ml) a Min-max ND , ,000 Mean ± SD 862±838 80,435±50,034 a Viral load was not measured in all cases; ND; not done. 222 Vol 36 No. 1 January 2005
3 subpopulations, CD3+, CD4+ and CD8+T-cell counts were determined using manufacture protocol. Briefly, whole blood was stained by monoclonal antibodies (DAKO Denmark). After staining and washing, red blood cells were lysed by FACS-lysing reagent and analyzed by the FACScan cytometer using Simulset (BD biosciences, San Jose, CA). Subtype identification For sera collected in 2002, HIV-1 subtypes of these samples were identified by V3 peptides ELISA using the CRF 01_AE peptide-tsi TIGPGQVFYRTG and the Thai B peptide-ksi HLGPGQAWYTTG, as previously described (Louisirirotchanakul et al, 1998). Since subtypes CRF 01-AE and Thai B were in the majority in Thailand, two V3 peptides, corresponding to the consensus sequences of subtype CRF 01_AE and subtype B, were used. Subtypes of samples were determined when the OD value of antibody to the V3 of a particular subtype was two times higher than the other. Only subtype CRF 01_AE samples were furthered investigating for the frequency and level of antibody against the gp41 epitope. Gp41 antibody titer The levels of anti-gp41 titer were measured by using the peptide-dqelleldkwalwns corresponding to the gp41 conserved region. The procedure for peptide ELISA has been described elsewhere (Louisirirotchanakul et al, 1999). Briefly, peptide was diluted and coated on an ELISA plate at 1 µg/ml overnight at room temperature. Serial two-fold dilutions of HIV-1 subtype CRF 01_AE (diluted from 1:100 to 1:28,000) were added and incubated for 1 hour, washed, and added to enzyme-conjugated goat anti-igg. After incubating and final washing, the substrate was added, and the reaction was stopped by sulfuric acid (1M). The optical density (OD) of the samples was measured. The OD of samples (at dilution 1:100) above the cut-off were considered to be positive. The antibody titers were expressed as the reciprocal of the serum endpoint dilution. The endpoint binding antibody titers were determined as the final dilution of serum which gave an OD greater than the cut-off value [(mean of 8-panel HIV-1 negative control + 3 standard deviations) x 2]. Sera with indeterminate results were omitted from the analysis. Statistical analysis The pattern of distribution of each panel of infected sera was tested by the Kolmogorov- Smirnov test. Data from all 3 panels of HIV-1 infected sera had non-gaussian distributions. Base on the non-parametric analysis, the differences in the antibody titers for the 3 independent panels were compared by the median test (SPSS version11.5). For the frequency of antibody in the diverse genetic subtypes, chi-square (Kruskal-Wallis test) was tested because of the limited number of sera in this panel. All p-values 0.05 were considered statistically significant. RESULTS The range of antibody titers against gp41 in AIDS patients and asymptomatic HIV-subtype CRF 01_AE infected subjects In this report, anti gp41 was screened at a dilution of 1:100. The frequencies of anti-gp41 positive antibody in all the infected sera were quite low (15-35%). The range of antibody titers from all 3 panels of infected sera from HIV-1 subtype CRF 01_AE was from less than 100 to 6,400. The median titers of these 3 panels were at 100. In the AIDS group, a total of 171 infected sera (14.6%) had a positive titer greater than 100. Among the higher titers of anti-gp41, a titer of 200 was found in 10.5%, at titer of 400 was found in 3.5%, and a titer of 800 was found in only 1 sample (0.3%). The highest titer, of 1,600 was found in only 1 sample (0.3%). The mean titer and standard deviations for the sera are 133±138 (Fig 1). There were two other panels of sera collected separately from the HIV-1 asymptomatic patients. The first panel was for 58 subjects collected in An antibody titer of greater than 100 was found in 17.2%. A titer of 200 was found in 6.9%, of 400 in 5.2%, and of 800 in 3.4%. A titer of 1,600 was found in 1 sample (1.7%). The mean titer and standard deviations were 172±238 (Fig 1). For the second panel, 71 sera were collected from asymptomatic patients in The data showed that 35.2% of samples had an anti-gp41 titer greater than 100. A titer Vol 36 No. 1 January
4 SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH gp 41 antibody titer Frequency of antibody (%) 6,400 3,200 1, Stage of disease Fig 1 The frequencies of anti-gp41 titers among the three panels of sera of HIV-1 subytpe CRF 01_AE infected patients compared n=58 n=71 Anti-gp 41 n=171 asymp 94 asymp 02 AIDS Subtype A Subtype B Subtype Subtype C Subtype D Subtype AE Subtype G Thai B Serum subtype Fig 2 The frequencies of anti-gp41 in various genetic subtypes of HIV-1 infection. All sera in each subtype were collected at random. of 200 was seen in 12.7%, of 400 in 8.5%, of 800 in 4.2%, of 1,600 in 4.2%, of 3,200 in 2.8%, and the highest titer at 6,400 was seen in 2.8%. The mean and standard deviations are 495±1,173 (Fig 1). An increase in the mean antibody titers was seen between 1994 and 2002 (172±238 in , 495±1,173 in 2002). The difference between anti-gp41 titers in sera from AIDS and asymptomatic persons By using the median test, it was found that the differences between the titers of anti-gp41 antibodies in the sera of these three panels were statistically significant. For the comparison between each pair of infected sera, the Mann- Whitney U test was used. A significant difference between the frequency of the anti-gp41 titers in the sera from the AIDS and asymptomatic persons collected in 2002 was observed (p=0.001). In contrast, the difference in the frequency of the antibody titers to this epitope in the sera from the AIDS and asymptomatic subjects collected in was not statistically significant (p=0.6). Comparison between the two panels of sera from the 2 separate groups of asymptomatic patients infected with HIV-1 subtype CRF 01_AE in and 2002 A higher concentration of anti-gp41 was observed in the panel of sera collected in The patients in these two asymptomatic groups were age and sex matched. The difference in frequency of the anti-gp41 antibody titers between the two asymptomatic groups was significant (p=0.05). Qualitative study of the level of antibody to envelope gp41 in HIV-1 subtypes A-G By evaluating sera from HIV-1 diverse genetic subtypes, the low seroreactivity of these epitopes has also been demonstrated. The gp41antibody in each subtype was screened at dilution 1:100. The binding reactivity of these samples with the gp41 peptide was 52.4% for subtype B (11 of 21), 44% for Thai B (8 of 18), 28% for subtype CRF 01_AE (24 of 87), 26% for subtype D (5 of 19), 25% for subtype A (4 of 16), 22% for subtype G (2 of 9), and 14% for subtype C (2 of 14). Our study indicates that among the various genetic subtypes of HIV-1, subtype B infected patients had the highest frequency of samples with titers were more than 100. Sera from HIV-1 subtype C had the lowest frequency of titers more than 100 (Fig 2). By statistical analysis (chi-square test), there was no significant difference between antibody titers in each pair of these subtypes (p=0.088). DISCUSSION In general, serum from HIV-1 infected persons contains antibodies that bind to an array of epitopes found on the surface envelope glycoproteins of whole viruses (Krause et al, 1997). Examining sera of HIV-1 infected patients in our study showed that binding antibody to this 224 Vol 36 No. 1 January 2005
5 epitope gp41-eldkwa was low to non-existent. These low responses were observed even in a subset of well characterized individuals with high levels of CD4+ and CD8+ T-cell responses. The relative rarity of such antibody specificity in human serum suggests that this region is poorly immunogenic and may be masked, or not exposed, on the surface of intact virions (Neurath et al, 1995; Sattentau, 1996; Nyambi et al, 1998; Sreepian et al, 2004). Despite the low antigenicity, the critical role of antibody against this epitope has been confirmed for its broad and potent protective activity (Burton et al, 1994). Previous studies indicated that antibody to this epitope showed neutralizing activity against primary isolates of several genetic subtypes of HIV- 1 (Zhang et al, 1997; Nyambi et al, 2000; Kitabwalla et al, 2003). In investigation the binding activity of antibody to this epitope, our results indicated that asymptomatic patients, whose sera were collected in 2002, showed higher levels of this specific antibody than sera from AIDS patients did. These observations suggest that antibody to this epitope is related to the stage of disease. To support this idea, another study has shown a sustained HIV-1 specific antibody response to HIV-1 primary isolates in HIV-1 positive non-progressors (Cao et al, 1995). In general, a correlation is seen between the decline in HIV-1 specific antibody and a poor prognosis. As shown in Table1, most of the patients with CD4+ T cell count less than 200 cells/ µl had lower levels of antibody to this epitope than asymptomatic persons. Lowering the CD4 count will likely contribute to a poor immune response in controlling viral load. In contrast, it had been reported that high levels of this neutralizing antibody can actively neutralize virus, lower the viral load, and maintain CD4+ T cells (Nokta et al, 2000). One possible interpretation for these results is that the presence of high viral loads in the serum has bound the available anti-gp41 antibodies, leaving a low concentration to react with the gp41 peptide. Reduction in antibody titers due to excess viral antigen has been described for various antibodies, particularly late in the natural history of HIV infection or in symptomatic HIV disease (Levy et al, 1985; Garland et al, 1996). An increasing viral load may affect the quantity and quality of antibody producing cells in recognizing specific antigens. In AIDS patients, viral loads may present B cells from responding to some epitopes and turn down antibody production by an unclear mechanism. Antibody production varies enormously in rate and efficiency, depending on several host and viral factors. Despite the similarity of host factors and viral factors between the two groups of asymptomatic subjects, binding antibody to this region was significantly higher in asymptomatic subjects whose sera were collected in In fact, improved responsiveness in both humoral and cellular immunity in antiretroviral treated patients was observed in most cases. Viral load decreased to undetectable (less than 50 copies/µl) levels while the CD4 count has been increased, stable or slowly decreased (Lempicki et al, 2000; Riou et al, 2000; Flepp et al, 2001). In the era before antiretroviral drugs, many infected persons were not treated or received inadequate treatment. Thus, the immune system deteriorated rapidly. Our data suggests that significantly higher levels of anti-gp41 in asymptomatic sera collected in 2002 may be due to antiretroviral treatment. This study supports the results of the HAART (Highly-Active Anti- Retroviral Therapy) trial showing immune restoration in HIV-1 infected persons (Kaufmann and Rosenberg, 2003). Considering viral factors, it can be seen that later viral sequences can be distinguished from earlier sequences (Markham et al, 1998; Srisurapanon et al, 2001). Although this epitope is highly conserved in various subtypes, mutation in this region (ELDKWA) had been described. Changing of amino acid in this region affects both epitope expression and/or cell-cell fusion (Cao et al, 1993; Poumbourios et al, 1995). An improvement in immunoresponsiveness by antiretroviral therapy and/or changing in the amino acid sequence may affect antibody responses. For these reasons, the concentration of anti-gp41 in the present is different from the past. By epitope mapping, this epitope (ELDKWA) in gp41 has been highly conserved in many genetic subtypes. Therefore, antibody to this epitope shows a stronger degree of cross subtype reactivity. In our study, the antibody response to this region in infected patients has not been effective in all the diverse subtypes of HIV- Vol 36 No. 1 January
6 SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH 1. The approximate frequency of antibody in subtypes A, D, E and G was about 25%. These results indicate that this region of gp41 was not accessible. However, slight differences in frequencies are seen in subtypes B and C. Several factors may account for these differences. First, some of these epitopes may be more immunogenic in one subtype than in others. Second, variance in ethnicity may account for the difference in immune response. Last, better treatment and more appropriate knowledge may have influenced immunity. HIV-1 subtype B infected patients are predominant in developed countries, while people infected with subtype C are usually found in developing countries. Considering viral factors, viral phenotype has also been associated with stages of disease (Koot et al, 1993). Unfortunately, viral phenotypes were not determined in this study. The frequency of antibody to gp41 (ELDKWA) does not significantly discriminate between genetic subtypes, since it reacts directly to a relatively conserved feature of the envelope glycoprotein. In conclusion, our data indicate that immunogenicity of this region is poor and highly conserved in diverse subtypes; concentration of antigp41 is related to the clinical stage of HIV-1 infection; concentrations of anti-gp41 in asymptomatic infected person from the past and in the present are different; and the responsiveness of the antibody to this region is not different in diverse genetic subtypes. ACKNOWLEDGEMENTS We are in debt to all the patients who participated in this study. This work was partially supported by Srinakharinwirot University. REFERENCES Albert J, Abrahamsson B, Nagy K, et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990; 4: Ariyoshi K, Harwood E, Chiengsong-Popov R, Weber J. Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? Lancet 1992; 340: Biron Z, Khare S, Samson A, Hayek Y, Naider F, Anglister J. A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. Biochemistry 2002; 41: Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266: Calarota S, Jansson M, Levi M, et al. Immunodominant glycoprotein 41 epitope identified by seroreactivity in HIV type 1-infected individuals. AIDS Res Hum Retrovir 1996; 12: Cao J, Bergeron L, Helseth E, Thali M, Repke H, Sodroski J. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol 1993; 67: Cao Y, Qin L, Zhang L, Safrit, J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332: Flepp M, Schiffer V, Weber R, Hirschel B. Modern anti- HIV therapy. Swiss Med Wkly 2001; 131: Garland FC, Garland CF, Gorham ED, Brodine SK. Western blot banding patterns of HIV rapid progressors in the US Navy seropositive cohort: implications for vaccine development. Navy Retroviral Working Group. Ann Epidemiol 1996; 6: Kaufmann D. Rosenberg E. The value of preserving HIV-specific immune responses. J HIV Ther 2003; 8: Kitabwalla M, Ferrantelli F, Wang T, et al. Primary African HIV clade A and D isolates: effective crossclade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res Hum Retrovir 2003; 19: Koot M, Keet IPM, Vos AHV, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118: Krause R, Dimmock N, Morens D. Summary of antibody workshop: The role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases. J Infect Dis 1997; 176: Lempicki RA, Kovacs JA, Baseler MW, et al. Impact of HIV-1 infection and highly active antiretroviral 226 Vol 36 No. 1 January 2005
7 therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. PNAS 2000; 97: Levy JA, Kaminsky LS, Morrow WJ, et al. Infection by the retrovirus associated with the acquired immunodeficiency syndrome: clinical, biological, and molecular features. Ann Intern Med 1985; 103: Louisirirotchanakul S, Beddows S, Cheingsong R, et al. Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand. J Acquir Immune Defic Syndr 1999; 21: Louisirirotchanakul S, Beddows S, Cheingsong-Popov R, et al. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: Markham RB, Wang WC, Weisstein AE, et al. Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. PNAS 1998; 95: Neurath A, Strick N, Lin K, Jiang S. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions. AIDS Res Hum Retrovir 1995; 11: Nokta M, Turk P, Loesch K, Pollard RB. Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count. Clin Diagn Lab Immunol 2000; 7: Nyambi PN, Gorny MK, Bastiani L, van der Groen G, WilliamsC, Zolla-Pazner S. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol 1998; 72: Nyambi PN, Nadas A, Mbah HA, et al. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol 2000; 74: Poumbourios P, el Ahmar W, McPhee DA, Kemp BE. Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J Virol 1995; 69: Purtscher M, Trkola A, Grassauer A, et al. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS 1996; 10: Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. PNAS 2003; 100: Riou M, Renier G, Mattman S, et al. Dynamic study of anti-hiv antibody avidity after cellular immunity restoration under antiretroviral treatment. Ann Biol Clin (Paris) 2000; 58: Robert-Guroff M, Brown M, Gallo R. HTLV-III-neutralizing antibodies in patients with AIDS and AIDSrelated complex. Nature 1985; 316: Sattentau Q. Neutralization of HIV-1 by antibody. Curr Opin Immunol 1996; 8: Sreepian A, Srisurapanon S, Horthongkham N, et al. Conserved neutralizing epitopes of HIV type 1 CRF 01_AE against primary isolates in long-term nonprogressors. AIDS Res Hum Retrovir 2004; 20: Srisurapanon S, Samransurp K, Tunsupasawasdeekul S, et al. Molecular and phenotypic characteristics of neurotropic HIV-1 subtype E. Southeast Asian J Trop Med Public Health 2001; 32: Stiegler G, Armbruster C, Vcelar B, et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 2002; 16: , Stiegler G. Katinger H. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J. Antimicrob Chemother 2003; 51: Weiss R, Clapham P, Cheingsong-Popov R, et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985; 316: Wolbank S, Kunert R, Stiegler G, Katinger H. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol 2003; 77: Zhang Y, Fracasso C, Fiore J, et al. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis 1997; 176: Vol 36 No. 1 January
Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ
www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons
More informationHIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
More informationEMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)
AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,
More informationSupplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood
Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood tree illustrating CRF01_AE gp120 protein sequence relationships between 107 Envs sampled in the RV144 trial
More informationAntibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center
Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationHIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual)
HIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual) BACKGROUND Human Immunodeficiency Virus ( HIV ) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationSEROLOGICAL DIAGNOSIS OF VIRAL INFECTIONS:
SEROLOGICAL DIAGNOSIS OF VIRAL INFECTIONS: POSSIBILITIES OF SEROLOGICAL DIAGNOSIS TYPES OF SEROLOGICAL REACTIONS SEROLOGICAL REACTIONS Ag-Ab reactions used for the detection of unknown Ag or Ab, in vitro
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationCD4 T Cell Decline Is Not Associated With Amino Acid Changes in HIV-1 gp120
CD4 T Cell Decline Is Not Associated With Amino Acid Changes in HIV-1 gp120 Colin Wikholm and Isai Lopez BIOL 368: Bioinformatics Laboratory Department of Biology Loyola Marymount University November 15,
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationCh 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems
Ch 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems Highlight Disease: Malaria World s dominant protozoal disease. Four species of Plasmodium: P. falciparum (malignant), P. vivax (begnin),
More informationLongitudinal Studies of Neutralizing Antibody Responses to Rotavirus in Stools and Sera of Children following Severe Rotavirus Gastroenteritis
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 1998, p. 897 901 Vol. 5, No. 6 1071-412X/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Longitudinal Studies of
More informationRegional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa
JOURNAL OF VIROLOGY, Mar. 2002, p. 2233 2244 Vol. 76, No. 5 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.5.2233 2244.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Regional Clustering
More informationBoosts Following Priming with gp120 DNA
Neutralizing Antibody Responses Induced with V3-scaffold Protein Boosts Following Priming with gp120 DNA Susan Zolla-Pazner NYU School of Medicine Problems with Whole Env Immunogens Poor induction of Abs
More informationA PROJECT ON HIV INTRODUCED BY. Abdul Wahab Ali Gabeen Mahmoud Kamal Singer
A PROJECT ON HIV INTRODUCED BY Abdul Wahab Ali Gabeen Mahmoud Kamal Singer Introduction: Three groups of nations have been identified in which the epidemiology of HIV(Human Immunodeficiency Virus) varies:
More informationIt takes more than just a single target
It takes more than just a single target As the challenges you face evolve... HIV mutates No HIV-1 mutation can be considered to be neutral 1 Growing evidence indicates all HIV subtypes may be prone to
More informationLecture 11. Immunology and disease: parasite antigenic diversity
Lecture 11 Immunology and disease: parasite antigenic diversity RNAi interference video and tutorial (you are responsible for this material, so check it out.) http://www.pbs.org/wgbh/nova/sciencenow/3210/02.html
More informationHuman Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set
Human Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set Catalog Number : SEK11695 To achieve the best assay results, this manual must be read carefully before using this product
More informationIdentification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist
Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1
More information5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1
Epidemiology 227 April 24, 2009 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 60 questions and 9 pages on the examination. Each question will count one point.
More informationDiagnostic Tests for HIV
Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,
More informationFayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
More informationLow ds/dn Does Not Correlate With High Variation of Amino Acid Sequences Along the gp120 Protein Structure
Low ds/dn Does Not Correlate With High Variation of Amino Acid Sequences Along the gp120 Protein Structure Zach Goldstein & Jordan Detamore BIOL 368: Bioinformatics Laboratory Department of Biology Loyola
More informationOn an individual level. Time since infection. NEJM, April HIV-1 evolution in response to immune selection pressures
HIV-1 evolution in response to immune selection pressures BISC 441 guest lecture Zabrina Brumme, Ph.D. Assistant Professor, Faculty of Health Sciences Simon Fraser University http://www3.niaid.nih.gov/topics/hivaids/understanding/biology/structure.htm
More informationClass-Specific Antibody Response in Acyclovir- Treated and Adenine Arabinoside-Treated Patients with Primary Genital Herpes Simplex Virus Infection
Microbiol. Immunol., 39(10), 795-799, 1995 Class-Specific Antibody Response in Acyclovir- Treated and Adenine Arabinoside-Treated Patients with Primary Genital Herpes Simplex Virus Infection Takashi Kawana*,1,
More informationHuman Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set
Human Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set Catalog Number : SEK11233 To achieve the best assay results, this manual must be read carefully before using this product
More informationHIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital
HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per
More informationORIGINAL ARTICLE /j x. Brescia, Italy
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00938.x Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive
More informationPrevention of infection 2 : immunisation. How infection influences the host : viruses. Peter
Prevention of infection 2 : immunisation How infection influences the host : viruses Peter Balfe, p.balfe@bham.ac.uk @pbalfeuk Let s have some LO s just for fun 1. Define the Immune response to viruses,
More informationDelay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies Alexandra Trkola 1, Herbert Kuster 1, Peter Rusert 1, Beda Joos 1, Marek Fischer
More informationOverview of role of immunologic markers in HIV diagnosis
Overview of role of immunologic markers in HIV diagnosis Savita Pahwa, M.D. Departments of Microbiology & Immunology and Pediatrics University of Miami, Miller School of Medicine, Miami, Florida Background:
More informationDissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors
JOURNAL OF VIROLOGY, June 2007, p. 6548 6562 Vol. 81, No. 12 0022-538X/07/$08.00 0 doi:10.1128/jvi.02749-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Dissecting the Neutralizing
More information, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic
1 Two attributes make AIDS unique among infectious diseases: it is uniformly fatal, and most of its devastating symptoms are not due to the causative agent Male to Male sex is the highest risk group in
More informationSupporting Information
Supporting Information Walker et al. 1.173/pnas.111753118 - JR-CSF 1 3 1 4 1 5 1 6 1 7 1 8 blank beads protein A beads JR-FL - 1 3 1 4 1 5 1 6 1 7 1 8 - MGRM-C26 1 3 1 4 1 5 1 6 1 7 1 8 reciprocal serum
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationApplication of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma
Excerpt from MACS&more Vol 8 1/2004 Application of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma L. Davis Lupo and Salvatore T. Butera HIV and Retrovirology Branch,
More informationViral Genetics. BIT 220 Chapter 16
Viral Genetics BIT 220 Chapter 16 Details of the Virus Classified According to a. DNA or RNA b. Enveloped or Non-Enveloped c. Single-stranded or double-stranded Viruses contain only a few genes Reverse
More informationZheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY. Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p.
Title Studies of SARS virus vaccines Author(s) Zheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p. 39-43 Issued
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationInfluenza or flu is a
Clinical and Research Area Infectious Diseases Influenza Virus Types A and B Influenza or flu is a respiratory illness that is caused by influenza viruses. Influenza viruses type A and type B cause seasonal
More informationReceived 9 June 1997/Accepted 7 October 1997
JOURNAL OF VIROLOGY, Jan. 1998, p. 286 293 Vol. 72, No. 1 0022-538X/98/$04.00 0 Copyright 1998, American Society for Microbiology Antibody-Dependent Cellular Cytotoxicity Directed against Cells Expressing
More informationMID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.
Life Cycle Diagnosis and Pathogenesis Scott M. Hammer, M.D. -1 Virion Entry Life Cycle of Entry -1 virion -1 Virus virion envelope Cell membrane receptor RELEASE OF PROGENY VIRUS REVERSE Co- TRANSCRIPTION
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationHIV-1 p24 Antigen ELISA Catalog Number:
INTENDED USE The RETRO-TEK HIV-1 p24 Antigen ELISA is supplied for research purposes only. It is not intended for use in the diagnosis or prognosis of disease, or for screening and may not be used as a
More informationDetection of neuraminidase-inhibiting antibodies for measurement of Influenza vaccine immunogenicity
Borgis New Med 2015; 19(4): 147-155 DOI: 10.5604/14270994.1191796 Detection of neuraminidase-inhibiting antibodies for measurement of Influenza vaccine immunogenicity *Mónika Rózsa 1, István Jankovics
More informationMID-TERM EXAMINATION
Epidemiology 227 May 2, 2007 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 75 questions and 11 pages on the examination. Each question will count one point. Notify
More informationMouse Anti-OVA IgM Antibody Assay Kit
Mouse Anti-OVA IgM Antibody Assay Kit Catalog # 3017 For Research Use Only - Not Human or Therapeutic Use INTRODUCTION Ovalbumin (OVA) is a widely used antigen for inducing allergic reactions in experimental
More informationImmunobiology 7. The Humoral Immune Response
Janeway Murphy Travers Walport Immunobiology 7 Chapter 9 The Humoral Immune Response Copyright Garland Science 2008 Tim Worbs Institute of Immunology Hannover Medical School 1 The course of a typical antibody
More informationA Summary of Clinical Evidence
A Summary of Clinical Evidence Supporting the use of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test to assist in the diagnosis of Human Immunodeficiency Virus (HIV) TAP HERE TO SEE THE PRODUCTS Table
More informationBiomedical Engineering for Global Health. Lecture 10 HIV/AIDS vaccine development
Biomedical Engineering for Global Health Lecture 10 HIV/AIDS vaccine development Review of lecture 9 How do vaccines work? Types ofvaccines: Review of lecture 9 Are vaccines effective? -Edward Jenner s
More informationSV40 Detection and Transmission: Does SV40 Circulate in Human Communities?
SV40 Detection and Transmission: Does SV40 Circulate in Human Communities? Keerti Shah, Dana Rollison and Raphael Viscidi Johns Hopkins Medical Institutions Baltimore, MD Background A large number of cancer
More informationLearning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016
New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationCitation for published version (APA): Von Eije, K. J. (2009). RNAi based gene therapy for HIV-1, from bench to bedside
UvA-DARE (Digital Academic Repository) RNAi based gene therapy for HIV-1, from bench to bedside Von Eije, K.J. Link to publication Citation for published version (APA): Von Eije, K. J. (2009). RNAi based
More informationMeasles is a chilhood disease caused
Paediatrica Indonesiana VOLUME 48 May 2008 NUMBER 3 Original Article Antigenic differences between wildtype measles viruses and vaccine viruses in Indonesia Made Setiawan 1, Agus Sjahrurachman 2, Fera
More informationWHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Murex HIV Ag/Ab Combination Number: PQDx
WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Murex HIV Ag/Ab Combination Number: PQDx 0144-043-00 Abstract Murex HIV Ag/Ab Combination with product codes 7G79-09 (GE41,
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More information7/14/2014. Multiple immune effector mechanisms contribute to protection influenza. What is a correlate of protection?
What is a correlate of protection? Immunological Assessment of Influenza Vaccines and Correlates of Protection Jacqueline Katz Influenza Division Centers for Disease Control and Prevention Defined immune
More informationThe humoral immune responses to IBV proteins.
The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural
More informationChapter 8. Slower CD4 T cell decline in Ethiopian versus Dutch HIV 1 infected individuals is due to lower T cell proliferation rates
Slower CD4 T cell decline in Ethiopian versus Dutch HIV 1 infected individuals is due to lower T cell proliferation rates Nienke Vrisekoop *1, Belete Tegbaru *1,2, Margreet Westerlaken 1, Dawit Wolday
More informationAre we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
More informationBroadly Neutralizing Antibodies for HIV Eradication
DOI 10.1007/s11904-016-0299-7 HIV PATHOGENESIS AND TREATMENT (AL LANDAY, SECTION EDITOR) Broadly Neutralizing Antibodies for HIV Eradication Kathryn E. Stephenson 1,2 & Dan H. Barouch 1,2 # The Author(s)
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More information2005 LANDES BIOSCIENCE. DO NOT DISTRIBUTE.
[Human Vaccines 1:2, 45-60; March/April 2005]; 2005 Landes Bioscience Review Role of Neutralizing Antibodies in Protective Immunity Against HIV Indresh K. Srivastava* Jeffrey B. Ulmer Susan W. Barnett
More informationNonsynonymous Amino Acid Mutations in gp120 Binding Sites are Related to Progression of HIV-1
Nonsynonymous Amino Acid Mutations in gp120 Binding Sites are Related to Progression of HIV-1 Matthew Allegretti and Anindita Varshneya BIOL 368: Bioinformatics Laboratory Loyola Marymount University November
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationIdentification of Microbes Lecture: 12
Diagnostic Microbiology Identification of Microbes Lecture: 12 Electron Microscopy 106 virus particles per ml required for visualization, 50,000-60,000 magnification normally used. Viruses may be detected
More informationSupporting Information
Supporting Information Valkenburg et al. 10.1073/pnas.1403684111 SI Materials and Methods ELISA and Microneutralization. Sera were treated with Receptor Destroying Enzyme II (RDE II, Accurate) before ELISA
More informationHIV Diagnostic Testing
In The name of God HIV Diagnostic Testing By : Dr. Shahzamani PhD of Medical virology Purpose of HIV Testing To identify asymptomatic individuals To diagnose HIV infection in those who practice high risk
More informationPractice Problems 8. a) What do we define as a beneficial or advantageous mutation to the virus? Why?
Life Sciences 1a Practice Problems 8 1. You have two strains of HIV one is a wild type strain of HIV and the second has acquired a mutation in the gene encoding the protease. This mutation has a dual effect
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationLow immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease
Low immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease Shailesh K. Choudhary 1 *, Nienke Vrisekoop 2 *, Christine A. Jansen 2, Sigrid A. Otto 2, Hanneke
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationChallenges in Designing HIV Env Immunogens for Developing a Vaccine
b514_chapter-13.qxd 12/4/2007 3:39 PM Page 327 Chapter 13 Challenges in Designing HIV Env Immunogens for Developing a Vaccine Indresh K. Srivastava* and R. Holland Cheng Summary HIV continues to be a major
More informationSupplementary information. Early development of broad neutralizing antibodies in HIV-1 infected infants
Supplementary information Early development of broad neutralizing antibodies in HIV-1 infected infants Leslie Goo, Vrasha Chohan, Ruth Nduati, Julie Overbaugh Supplementary Figure 1. Neutralization profile
More informationMeasles IgM ELISA Kit
Measles IgM ELISA Kit Catalog Number KA2257 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of the Assay...
More informationRemoval of N-Linked Glycosylation Sites in the V1 Region of Simian Immunodeficiency Virus gp120 Results in Redirection of B-Cell Responses to V3
JOURNAL OF VIROLOGY, Feb. 2004, p. 1525 1539 Vol. 78, No. 3 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.3.1525 1539.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Removal of
More informationKelly A. Curtis, M. Susan Kennedy, Kevin Delaney, Man Charurat, and S. Michele Owen
Kelly A. Curtis, M. Susan Kennedy, Kevin Delaney, Man Charurat, and S. Michele Owen Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA Advantages: Obvious evolution
More informationComplicated viral infections
Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationDownloaded by on April 28, 2018 https://pubs.acs.org Publication Date: April 24, 1984 doi: /bk
1 Virus-Receptor Interactions BERNARD N. FIELDS Department of Microbiology and Molecular Genetics, Harvard Medical School, and Department of Medicine (Infectious Disease), Brigham and Women's Hospital,
More informationMouse Total IgA Antibody Detection Kit
Mouse Total IgA Antibody Detection Kit Catalog # 3019 For Research Use Only - Not Human or Therapeutic Use INTRODUCTION The total IgA levels in specimens are often determined in mouse disease models involving
More informationTSH Receptor Monoclonal Antibody (49) Catalog Number MA3-218 Product data sheet
Website: thermofisher.com Customer Service (US): 1 800 955 6288 ext. 1 Technical Support (US): 1 800 955 6288 ext. 441 TSH Receptor Monoclonal Antibody (49) Catalog Number MA3-218 Product data sheet Details
More informationChapter 13 Viruses, Viroids, and Prions. Biology 1009 Microbiology Johnson-Summer 2003
Chapter 13 Viruses, Viroids, and Prions Biology 1009 Microbiology Johnson-Summer 2003 Viruses Virology-study of viruses Characteristics: acellular obligate intracellular parasites no ribosomes or means
More informationHIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)
HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationJOURNAL OF VIROLOGY, Feb. 1999, p Vol. 73, No. 2. Copyright 1999, American Society for Microbiology. All Rights Reserved.
JOURNAL OF VIROLOGY, Feb. 1999, p. 1740 1745 Vol. 73, No. 2 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Comparison of the Antibody Repertoire Generated
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationSP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World
MIT OpenCourseWare http://ocw.mit.edu SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World Spring 2009 For information about citing these materials or our
More informationHIV-1 ICx/CRx Kit Reagents for Immune Dissociation and Reactivity Confirmation
INTENDED USE The RETRO-TEK HIV-1 IC x/cr x Kit is supplied for research purposes only. It is not intended for use in the diagnosis or prognosis of disease or for screening and may not be used as a confirmatory
More informationJ. D. Trujillo,* N. M. Kumpula-McWhirter, K. J. Hötzel, M. Gonzalez, and W. P. Cheevers
JOURNAL OF VIROLOGY, Sept. 2004, p. 9190 9202 Vol. 78, No. 17 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.17.9190 9202.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Glycosylation
More information3. Lymphocyte proliferation (fig. 15.4): Clones of responder cells and memory cells are derived from B cells and T cells.
Chapter 15 Adaptive, Specific Immunity and Immunization* *Lecture notes are to be used as a study guide only and do not represent the comprehensive information you will need to know for the exams. Specific
More informationFor questions 1-5, match the following with their correct descriptions. (24-39) A. Class I B. Class II C. Class III D. TH1 E. TH2
Questions Made by SI ATTENDEES!! :) Page 1 of 6 Student-Made Practice Exam Activity All questions, answers, and slide numbers are based off of Monday s SI activity, where students/attendees created possible
More informationSupporting Online Material for
www.sciencemag.org/cgi/content/full/1175194/dc1 Supporting Online Material for A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection John S. Yi, Ming Du, Allan J. Zajac* *To whom
More information